Just been looking at Cardinal Health and honestly the setup here is pretty interesting for anyone building a healthcare stock position. The company's been delivering solid results lately - pharmaceutical segment revenue jumped 19% to $61 billion in their recent quarter, with segment profit climbing 29%. That's the kind of momentum that catches attention.

What's catching my eye most is their pivot toward specialty pharmaceuticals. They're projecting specialty revenues will hit $50 billion this fiscal year, which signals a real shift away from low-margin commodity distribution toward higher-margin therapies like oncology and urology. That's a meaningful strategic move for a health care stock that's been traditionally viewed as just a middleman.

Their adjacent businesses are firing on all cylinders too. Nuclear and Precision Health Solutions, at-home care, and logistics operations combined for 34% revenue growth and 52% profit growth last quarter. Theranostics alone grew over 30% with more than 70 products in the pipeline. This diversification matters because it reduces dependence on the thin-margin core distribution business.

There's also the GMPD turnaround story - their medical products segment profit basically doubled year-over-year from $18 million to $37 million. If they keep executing on operational improvements and supply chain efficiency, this segment could finally stop being a drag on overall profitability.

Now the realistic part - they're guiding for profit growth to moderate to mid-teens in the second half, partly because they're lapping some one-time customer onboarding from last year. Tariffs are also creating headwinds for the medical segment. And yeah, the core pharmaceutical distribution business will always be structurally thin-margin due to high volume dependence.

But here's what matters: estimates have been revising upward. EPS consensus improved 2.7% over the past month to $10.31, and Q3 revenue guidance sits at $62.42 billion, up 13.7% year-over-year. This health care stock has beaten earnings estimates four quarters running with an average surprise of 9.3%.

The market's already recognized some of this - shares are up 49% over six months versus 23% for the broader healthcare industry. Still, if the specialty pivot and operational turnarounds continue, there's room for this health care stock to keep running. Worth keeping on your radar if you're looking at the sector.